Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Dotarem

ApprovedSmall molecule

Dotarem is one of 97 small molecule programs targeting Brain Glioma. It is currently in Approved.

3

Indications

14

Total Trials

2

Active Trials

96

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain GliomaActive, not recruiting

Peripheral Arterial DiseaseActive, not recruiting

Interstitial Lung DiseaseActive, not recruiting

Brain GliomaPhase 3

Active, not recruiting

Peripheral Arterial DiseaseApproved

Active, not recruiting

Interstitial Lung DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

101 competitors in Peripheral Arterial Disease

#DrugCompanyPhaseTrials

Ozempic

Foundayo

Viagra

VViatris Specialty LLC

Singulair

OOrganon and Co

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Omacor

Ticlid

Kuvan

BioMarin Pharmaceutical

Savaysa

Dotarem

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Alzheimer's Disease

NCT06600880

Clinical

Trials by Indication[1]

MRI2 trials

Intra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRI

Completed·PPhoenix Children's Hospital··NCT03023566·250 enrolled

Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.

Completed· Bayer logo

Bayer·Phase 4·NCT00764387·166 enrolled

CAR2 trials

Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

Completed·GGuerbet·Phase 3·NCT01010932·222 enrolled

Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

Completed·GGuerbet·Phase 3·NCT01012674·211 enrolled

MPA2 trials

Crossover Comparison of MultiHance and Dotarem

Completed·BBracco Diagnostics, Inc·Phase 4·NCT02070380·179 enrolled

Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)

Terminated·GGuerbet·Phase 3·NCT00980681·13 enrolled

Alzheimer's Disease1 trial

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

Not yet recruiting·—·Phase 1·NCT06600880·6 enrolled

Age1 trial

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

Completed·VVanderbilt University Medical Center··NCT03910114·500 enrolled

6 more indications

Brain Tumors1 trial

Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors

Completed·GGuerbet·Phase 4·NCT02034708·279 enrolled

Pediatric1 trial

DOTAREM Pharmacokinetics and Safety Study in Pediatric Subjects Aged < 2 Years

Completed·GGuerbet·Phase 4·NCT02411201·51 enrolled

Central Nervous System1 trial

Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions

Completed·GGuerbet·Phase 3·NCT01211873·416 enrolled

Brain Glioma1 trial

Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas

Completed·GGuerbet·Phase 3·NCT06057168·138 enrolled

Interstitial Lung Disease1 trial

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

Recruiting·MMassachusetts General Hospital·Phase 2·NCT05417776·30 enrolled

Peripheral Arterial Disease1 trial

Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease

Completed·GGuerbet·Phase 4·NCT01026389·189 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Dotarem. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dotarem compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dotarem. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Bayer

Related News